The complement system is a critical arm of innate immunity consisting of more than thirty plasma and cell-surface proteins that form a proteolytic cascade activated by pathogen-associated molecular patterns, immune complexes, and damaged cell surfaces. Dysregulated complement activation drives tissue injury in a diverse group of diseases, including rare hematological disorders, glomerulonephritis, and neuromuscular diseases, making specific complement proteins highly tractable therapeutic targets.
Three Activation Pathways Converging on C3 (Complement Component 3). The complement system is activated through three distinct pathways, each initiated by different recognition molecules but converging on a shared central amplification step. The classical pathway (CP) is triggered by the binding of C1q (complement component 1q, the recognition subunit of the C1 (complement component 1) complex, comprising C1q, C1r, and C1s) to antibody-antigen complexes — specifically to the Fc regions of IgG1, IgG2, IgG3, or IgM antibodies bound to antigen — causing C1r and C1s serine protease activation, sequential cleavage of C4 (complement component 4) and C2 (complement component 2), forming the classical pathway C3 convertase (C4b2a).
Lectin and Alternative Pathways. The lectin pathway (LP) is triggered by pattern recognition molecules — primarily mannose-binding lectin (MBL), ficolins, and collectin proteins — that bind carbohydrate motifs on microbial and damaged cell surfaces, activating MBL-associated serine proteases (MASPs, specifically MASP-1 and MASP-2) which cleave C4 and C2 to form the same C4b2a convertase as the classical pathway. The alternative pathway (AP) operates as a continuous low-level surveillance mechanism: spontaneous hydrolysis of C3 (the "tick-over" mechanism) generates C3(H2O), which associates with Factor B and Factor D to form the initial alternative pathway C3 convertase; this is amplified on pathogen and damaged cell surfaces lacking host complement regulatory proteins such as CD46 (membrane cofactor protein, MCP), CD55 (decay-accelerating factor, DAF), and CD59 (protectin). All three pathways converge on the cleavage of C3 into C3a (a potent anaphylatoxin and chemoattractant) and C3b (an opsonin that deposits on target surfaces and amplifies complement activation by forming additional C3 and C5 (complement component 5) convertases).1
The Terminal Complement Complex and Inflammatory Mediators. The C5 convertases generated by all three pathways cleave C5 into C5a and C5b. C5a (complement component 5a) is the most potent complement-derived inflammatory mediator, binding to the C5a receptor 1 (C5aR1, also called CD88) on neutrophils, monocytes, macrophages, mast cells, and endothelial cells to trigger degranulation, reactive oxygen species (ROS) production, cytokine release, and neutrophil chemotaxis. C5a also acts on C5a receptor 2 (C5aR2, C5L2) with partially anti-inflammatory effects. C5b nucleates the terminal complement complex (TCC), also called the membrane attack complex (MAC), by sequential recruitment of complement components C6 (complement 6), C7 (complement 7), C8 (complement 8), and multiple C9 (complement 9) molecules; polymerization of C9 forms a transmembrane pore in the target cell membrane, causing colloid osmotic lysis of bacterial cells, erythrocytes (in paroxysmal nocturnal hemoglobinuria, PNH), and other complement-susceptible cells. The anaphylatoxins C3a and C5a also activate mast cells and contribute to systemic inflammatory responses. Host cells are normally protected from terminal complement lysis by membrane-bound regulatory proteins including CD59, which blocks C9 polymerization, and CD55, which accelerates decay of the C3 and C5 convertases.12
Therapeutic Rationale: Complement-Mediated Diseases. The clinical spectrum of complement-mediated diseases spans hematology, nephrology, neurology, and inflammatory disease. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIGA (phosphatidylinositol glycan biosynthesis class A) gene in hematopoietic stem cells, resulting in deficiency of GPI (glycosylphosphatidylinositol)-anchored complement regulatory proteins CD55 and CD59 on erythrocyte and platelet surfaces; without these regulators, erythrocytes and platelets are destroyed by uncontrolled complement activation, causing hemolytic anemia, thrombosis, and cytopenias. Atypical hemolytic uremic syndrome (aHUS) is caused by mutations or autoantibodies affecting alternative pathway regulatory proteins (Factor H, Factor I, MCP/CD46), leading to uncontrolled alternative pathway activation in the renal microvasculature, causing thrombotic microangiopathy (TMA) with hemolytic anemia, thrombocytopenia, and acute kidney injury.
Complement-Mediated Renal and Neurological Diseases. Complement-mediated disorders of the kidney include C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (MPGN). In neurology, neuromyelitis optica spectrum disorder (NMOSD) caused by anti-AQP4 (aquaporin-4) antibodies activates complement at the blood-brain barrier, causing astrocyte destruction; generalized myasthenia gravis (MG) with anti-AChR antibodies activates terminal complement at the neuromuscular junction. These diseases define the indications for complement inhibitors.2
CD59 (protectin): Blocks C9 polymerization → prevents MAC formation on host cells. Absent in PNH → erythrocyte lysis. CD55 (DAF, decay-accelerating factor): Accelerates decay of C3 and C5 convertases. Absent in PNH. CD46 (MCP, membrane cofactor protein): Cofactor for Factor I-mediated cleavage of C3b and C4b. Loss-of-function mutations → aHUS. Factor H: Plasma protein that binds C3b and acts as cofactor for Factor I; prevents alternative pathway amplification in fluid phase and on self-surfaces. Mutations in Factor H (or anti-Factor H autoantibodies) → aHUS and C3G. Factor I: Serine protease that degrades C3b and C4b with Factor H or MCP as cofactors; loss-of-function → uncontrolled C3 consumption → secondary C3 deficiency and aHUS.
Complement inhibition has moved from a single approved agent (eculizumab, 2007) to a growing armamentarium targeting multiple points in the complement cascade. Agents targeting C5 (terminal complement), C3 (the central amplification point), the C5a receptor, and alternative pathway components now provide precise intervention at different levels of the cascade for different disease indications.
Eculizumab: First-in-Class Terminal Complement Inhibitor. Eculizumab is a humanized IgG2/IgG4 hybrid monoclonal antibody that binds with high affinity to C5, preventing its cleavage into C5a and C5b by the C5 convertase; this blocks both C5a-mediated inflammation and MAC (membrane attack complex) formation without affecting the upstream opsonization functions of C3b, which remain intact. Eculizumab was the first complement inhibitor approved by the FDA, receiving approval for paroxysmal nocturnal hemoglobinuria (PNH) in 2007 and aHUS in 2011, subsequently followed by approval for generalized myasthenia gravis (gMG) with anti-AChR antibodies and NMOSD (neuromyelitis optica spectrum disorder) with anti-AQP4 antibodies. In PNH, eculizumab reduces intravascular hemolysis, transfusion requirements, and thrombotic events, and improves quality of life and survival; the risk of thrombosis, which is driven by platelet complement activation in PNH, is substantially reduced.
Eculizumab in aHUS and Meningococcal Risk. In aHUS (atypical hemolytic uremic syndrome), eculizumab prevents thrombotic microangiopathy (TMA) recurrence and is continued long-term in patients with mutations in complement regulatory genes. Eculizumab is administered as an intravenous infusion, with an induction phase of weekly infusions followed by maintenance every two weeks. Because the terminal complement complex is a critical defense against encapsulated bacteria, particularly Neisseria meningitidis (meningococcus), all patients receiving eculizumab must be vaccinated against meningococcal disease with both the meningococcal ACWY (serogroups A, C, W, Y) polysaccharide conjugate vaccine and the meningococcal type B (MenB) vaccine at least two weeks before the first dose; prophylactic antibiotics (penicillin V or amoxicillin) are also recommended for the duration of therapy and for several months after discontinuation.3
Ravulizumab: Long-Acting Anti-C5 with Extended Dosing Interval. Ravulizumab is a modified humanized anti-C5 monoclonal antibody engineered from eculizumab through four amino acid substitutions that alter its pH-dependent binding to C5 and significantly increase its affinity for the neonatal Fc receptor (FcRn), extending its plasma half-life from approximately 11 days (eculizumab) to approximately 49 to 52 days. The practical consequence of this extended half-life is that ravulizumab requires dosing every 8 weeks in adults (after a loading dose) rather than every 2 weeks for eculizumab, substantially reducing the burden of intravenous infusions for patients with chronic lifelong conditions. Ravulizumab has the same mechanism of action as eculizumab (C5 cleavage blockade), the same indications (PNH, aHUS, gMG, NMOSD), and the same meningococcal vaccination and antibiotic prophylaxis requirements. Clinical non-inferiority to eculizumab has been demonstrated in PNH and aHUS in phase 3 trials. Because the mechanism is identical, the clinical decision between eculizumab and ravulizumab primarily rests on practical considerations of dosing frequency, intravenous access, and patient preference.4
Avacopan: C5aR1 Antagonist in Vasculitis. Avacopan is an oral small-molecule antagonist of C5a receptor 1 (C5aR1, CD88). Avacopan is approved for AAV (ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis), blocking C5a binding on neutrophils and macrophages, preventing C5a-mediated neutrophil priming, degranulation, and tissue infiltration without blocking MAC formation or C3b opsonization. It targets a different point from eculizumab: rather than preventing C5 cleavage, avacopan allows C5 cleavage but blocks the receptor through which C5a drives tissue inflammation. This distinction has clinical significance: avacopan preserves some complement-mediated defense against encapsulated bacteria (since MAC formation is unaffected), potentially reducing the catastrophic meningococcal risk of anti-C5 therapy. Avacopan is approved for ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis (AAV), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), in combination with standard therapy (rituximab or cyclophosphamide). In the ADVOCATE (Avacopan Co-administration with Standard Treatment for ANCA-associated Vasculitis Evaluation) trial, avacopan was non-inferior to high-dose corticosteroid tapering for remission induction and superior for sustained remission at 52 weeks, establishing it as a steroid-sparing strategy in ANCA vasculitis. The rationale for complement inhibition in ANCA vasculitis is that ANCA-activated neutrophils release granule contents and generate C5a, creating a destructive positive-feedback loop in the renal glomerulus and pulmonary microvasculature; blocking C5aR1 interrupts this loop and reduces neutrophil-driven endothelial damage.5
Pegcetacoplan: C3 Inhibitor for Proximal Complement Blockade. Pegcetacoplan is a pegylated cyclic peptide that inhibits C3 (complement component 3) and its cleavage fragment C3b by binding directly to C3 and C3b with high affinity, preventing both C3 convertase-mediated amplification and C3b opsonization; this provides inhibition at the central convergence point of all three complement activation pathways, upstream of all downstream effects including C5a generation, MAC formation, and C3b opsonization. Pegcetacoplan is approved for PNH, particularly addressing the residual extravascular hemolysis that persists in approximately 30% of PNH patients treated with anti-C5 agents (eculizumab or ravulizumab): when the terminal complement complex is blocked by anti-C5 therapy, C3b continues to deposit on PNH erythrocytes because C5 inhibition does not prevent C3 cleavage; erythrocytes opsonized with C3b are then removed by the reticuloendothelial system in the liver and spleen (extravascular hemolysis). Pegcetacoplan, by blocking C3, prevents both the intravascular hemolysis (through MAC blockade) and the extravascular hemolysis (through prevention of C3b opsonization), making it more effective than anti-C5 therapy for patients with clinically significant extravascular hemolysis. It is administered subcutaneously twice weekly. Because C3 inhibition affects all three complement pathways and opsonization, the infection risk — including for encapsulated bacteria — is potentially broader than with anti-C5 inhibitors, and meningococcal vaccination is required.2
Alternative Pathway Inhibitors: Iptacopan and Danicopan. Two oral agents targeting the alternative pathway amplification loop represent the most recently approved complement inhibitors. Iptacopan is an oral small-molecule inhibitor of Factor B (FB), the serine protease that associates with C3b to form the alternative pathway C3 convertase (C3bBb); by inhibiting Factor B, iptacopan prevents alternative pathway amplification while leaving the classical and lectin pathways intact, which preserves a broader component of innate immune defense than upstream inhibitors. Iptacopan is approved as monotherapy for PNH in adults, and clinical trials demonstrated superiority over anti-C5 therapy in reducing extravascular hemolysis and improving hemoglobin levels. Danicopan is an oral Factor D inhibitor; Factor D (FD) is the serine protease that cleaves Factor B within the alternative pathway C3 convertase complex. Danicopan was approved as an add-on therapy to eculizumab or ravulizumab in PNH patients with clinically significant extravascular hemolysis that persists despite anti-C5 therapy, targeting the same residual hemolysis problem as pegcetacoplan but via the alternative pathway rather than C3. As selective alternative pathway inhibitors, iptacopan and danicopan carry a meningococcal infection risk related to their role in complement-mediated defense against encapsulated bacteria, and meningococcal vaccination is required before therapy initiation for both agents.45
Terminal complement complex (MAC) is the primary defense against Neisseria meningitidis (meningococcus) and other encapsulated Gram-negative bacteria. All complement inhibitors increase the risk of meningococcal disease, which can be fulminant and fatal within hours. Mandatory before any complement inhibitor: Meningococcal ACWY polysaccharide conjugate vaccine AND MenB vaccine (Bexsero or Trumenba) at least 2 weeks before the first dose; if urgent treatment is needed, start prophylactic antibiotics (penicillin V 250 mg twice daily or amoxicillin 250 mg twice daily) until at least 2 weeks after vaccination. Prophylactic antibiotics should be continued throughout therapy. Patient education about early meningococcal symptoms (sudden headache, fever, stiff neck, petechial rash, photophobia) and the need for immediate emergency evaluation is mandatory. Some centers continue antibiotic prophylaxis indefinitely during complement inhibitor therapy.
Intravenous immunoglobulin (IVIG) is a pooled polyspecific IgG preparation derived from the plasma of thousands of healthy donors. Despite decades of clinical use across a broad range of autoimmune, inflammatory, and neurological diseases, the mechanisms by which IVIG suppresses pathogenic immune responses are multiple, dose-dependent, and incompletely understood. IVIG is among the most versatile immunological therapies available, with both replacement and immunomodulatory indications.
IVIG Mechanisms: Multiple Converging Pathways. The immunomodulatory effects of IVIG operate through several distinct mechanisms that are dose-dependent and likely disease-specific. At high doses (used for immunomodulatory indications, typically 1 to 2 g/kg), IVIG saturates the neonatal Fc receptor (FcRn), which is responsible for IgG recycling and extended plasma half-life; saturation of FcRn causes accelerated catabolism of endogenous IgG, reducing the circulating half-life of pathogenic autoantibodies by 10 to 14 days and producing a net reduction in autoantibody levels, which is particularly relevant in antibody-mediated autoimmune diseases. A second major mechanism is blockade of activating Fc-gamma receptors (FcgammaRII and FcgammaRIII) on macrophages, dendritic cells, and NK (natural killer) cells by IVIG-derived IgG Fc regions; this prevents phagocytosis of opsonized cells and antibody-dependent cellular cytotoxicity (ADCC), which is the mechanism most relevant to immune thrombocytopenic purpura (ITP), where platelet destruction by splenic macrophages is the primary pathology. A third mechanism involves the anti-idiotypic network: IVIG contains a broad repertoire of antibody specificities, including antibodies directed against the antigen-binding regions (idiotypes) of pathogenic autoantibodies, which can neutralize them directly. IVIG also modulates complement activation, B-cell function, T-cell activation, and cytokine production.6
Clinical Indications for IVIG. IVIG has two broad categories of use. The first is immunoglobulin replacement therapy in primary and secondary immunodeficiency states: primary antibody deficiency syndromes (common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), hyper-IgM syndrome), secondary antibody deficiency (chronic lymphocytic leukemia (CLL), multiple myeloma, post-hematopoietic stem cell transplant (HSCT) hypogammaglobulinemia). In these conditions, IVIG restores functional antibody levels and reduces recurrent bacterial infections; the goal trough IgG level is typically above 500 to 700 mg/dL in replacement dosing (usually 400 to 600 mg/kg monthly). The second category is high-dose immunomodulatory therapy: Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), ITP, Kawasaki disease, dermatomyositis, pemphigus vulgaris, myasthenia gravis crisis, and other antibody-mediated autoimmune diseases. The dosing for immunomodulatory indications is typically 1 to 2 g/kg total, given over 2 to 5 days, and may be repeated monthly for chronic conditions such as CIDP or MMN.6
IVIG Adverse Effects and Infusion Management. The most common adverse effects of IVIG are infusion-related reactions: headache, flushing, chills, fever, nausea, and back pain, which occur in 5 to 15% of infusions and are typically mild and transient. Slowing the infusion rate and pre-medication with acetaminophen and diphenhydramine reduce these reactions. Aseptic meningitis occurs in a small proportion of patients, typically within 24 hours of infusion, and is more common with high-dose regimens; it is self-limiting and resolved with symptomatic treatment. A serious but uncommon adverse effect is thromboembolic events (deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and stroke), occurring particularly in older patients with pre-existing cardiovascular risk factors; the mechanism involves IVIG-induced increases in plasma viscosity and platelet aggregation, and the risk is reduced by infusing at lower rates and adequate hydration.
IVIG Hematological and Renal Adverse Effects. Hemolytic anemia can occur due to anti-blood group antibodies (anti-A, anti-B) present in some IVIG lots; patients with non-O blood groups receiving large doses are at higher risk. Acute kidney injury (AKI) has been associated with sucrose-stabilized IVIG formulations (which are no longer preferred) due to osmotic nephropathy in tubular cells; modern maltose- or glycine-stabilized formulations carry lower renal risk. All commercially available IVIG preparations should be checked for IgA content in patients with selective IgA deficiency, who may have anti-IgA antibodies and are at risk for anaphylaxis from IgA in the IVIG preparation; IgA-depleted IVIG preparations are available for this population.6
Subcutaneous immunoglobulin (SCIG) is an alternative formulation allowing self-administration at home, typically as a weekly or biweekly subcutaneous injection. SCIG produces steadier IgG serum levels without the peaks and troughs of monthly IVIG infusions, which is advantageous in immunodeficiency replacement therapy. SCIG is generally better tolerated than IVIG (fewer systemic infusion reactions) because the slower absorption rate avoids the high peak IgG levels that trigger systemic reactions. However, SCIG is not used for high-dose immunomodulatory indications (such as Guillain-Barré syndrome or ITP), where high peak IgG concentrations achieved by intravenous dosing appear to be necessary for the therapeutic effect. The choice between IVIG and SCIG for replacement indications is driven by patient preference, venous access, and quality-of-life considerations.
T-cell and B-cell activation require both a primary antigen-specific signal through the T-cell receptor (TCR) or B-cell receptor (BCR) and a co-stimulatory signal through accessory receptor-ligand pairs. Pharmacological blockade of these co-stimulatory checkpoints provides a mechanism to selectively inhibit antigen-driven immune activation without the broad suppression of conventional immunosuppressants, and has proven effective in both autoimmune disease and transplant rejection prevention.
Abatacept: T-Cell Co-stimulation Blockade. For full T-cell activation, the TCR-mediated antigen recognition signal must be accompanied by a co-stimulatory signal delivered by engagement of CD28 (cluster of differentiation 28) on the T-cell surface by its ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs). In the absence of this co-stimulatory signal, antigen-specific T cells become anergic (unresponsive) or undergo apoptosis rather than proliferating and differentiating into effector cells. Abatacept is a recombinant fusion protein consisting of the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) fused to the Fc region of human IgG1; because CTLA-4 binds CD80 and CD86 with approximately 500 to 2500-fold higher affinity than CD28, abatacept competitively occupies both CD80 and CD86 on APCs, preventing CD28 engagement and thereby delivering an incomplete, anergy-inducing signal to antigen-specific T cells. Abatacept is approved for moderate-to-severe RA (second-line after methotrexate failure), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), and the prevention of acute graft-versus-host disease (aGVHD) in hematopoietic stem cell transplant (HSCT). In RA, abatacept reduces synovitis, joint damage, and disability with an efficacy comparable to tumor necrosis factor (TNF) inhibitors but with a different mechanism that is advantageous in patients with seropositive RA (anti-CCP or RF positive), in whom T-cell-driven pathology appears more prominent.
Belatacept: High-Affinity CD80 and CD86 Blocker in Kidney Transplantation. Belatacept is a second-generation CTLA-4-Ig fusion protein with two amino acid substitutions relative to abatacept (L104E and A29Y) that confer approximately 10-fold higher binding affinity to CD80 and CD86, producing more complete co-stimulation blockade. Belatacept is approved for prophylaxis of organ rejection in kidney transplant recipients in combination with basiliximab (anti-CD25) induction, mycophenolate, and corticosteroids. The key advantage of belatacept over calcineurin inhibitor-based (CNI-based) regimens (cyclosporine, tacrolimus) is the preservation of renal function over time: because belatacept does not have the vasoconstricting, nephrotoxic, and pro-fibrotic effects of calcineurin inhibitors, patients on belatacept maintain better long-term estimated glomerular filtration rate (eGFR) and reduced incidence of chronic allograft nephropathy. The trade-off is a higher rate of acute rejection in the first year compared to CNI-based regimens, particularly in EBV (Epstein-Barr virus)-seronegative recipients at risk for post-transplant lymphoproliferative disorder (PTLD), which is a contraindication to belatacept use. Belatacept is administered intravenously monthly after the transplant period.7
Ibrutinib, Acalabrutinib, and Zanubrutinib. These are inhibitors of BTK (Bruton tyrosine kinase), a non-receptor tyrosine kinase expressed in B cells, mast cells, macrophages, platelets, and other hematopoietic cells; it is a critical downstream signaling component of the B-cell receptor (BCR) signaling pathway and is also involved in Fc-gamma receptor, Toll-like receptor (TLR), and CXCR4 (C-X-C chemokine receptor type 4) signaling. BCR engagement activates BTK through a kinase cascade: SRC (sarcoma kinase)-family kinase LYN (Lck/Yes-related novel tyrosine kinase) activates SYK (spleen tyrosine kinase), which recruits and activates BTK, and activated BTK phosphorylates phospholipase C-gamma2 (PLC-gamma2), generating second messengers that activate NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), ERK (extracellular signal-regulated kinase), and other transcription factors driving B-cell survival, proliferation, and differentiation. Ibrutinib is a first-generation covalent (irreversible) BTK inhibitor that forms a covalent bond with cysteine-481 in the BTK active site; it also inhibits multiple related kinases (ITK, EGFR, TEC, RLK), which accounts for some of its off-target adverse effects. Acalabrutinib and zanubrutinib are second-generation covalent BTK inhibitors with greater BTK selectivity, reducing the cardiovascular and bleeding adverse effects of ibrutinib. All three are approved for hematological malignancies (CLL (chronic lymphocytic leukemia), mantle cell lymphoma, Waldenström macroglobulinemia).89
BTK Inhibitors in Autoimmune Disease. The rationale for BTK inhibition in autoimmune disease is multifaceted: blocking BCR signaling in autoreactive B cells prevents their activation and autoantibody production; blocking BTK-dependent mast cell and macrophage signaling reduces innate immune amplification; and blocking BTK in plasmablasts and some plasma cell precursors may reduce autoantibody secretion. Ibrutinib has demonstrated activity in immune thrombocytopenic purpura (ITP), pemphigus vulgaris, and warm autoimmune hemolytic anemia (wAIHA) in clinical studies, though it is not currently approved for autoimmune indications. Emerging BTK inhibitors designed specifically for autoimmune disease (including fenebrutinib and evobrutinib) have been investigated in multiple sclerosis, Sjögren syndrome, and systemic lupus erythematosus (SLE); the BTK pathway is particularly relevant in antibody-mediated autoimmune diseases where B-cell activation and plasma cell differentiation drive pathology. A key safety concern with BTK inhibitors is cardiovascular toxicity: ibrutinib is associated with atrial fibrillation (AF) in approximately 10 to 16% of patients, thought to be related to off-target inhibition of ITK (interleukin-2 (IL-2)-inducible T-cell kinase) and PI3K (phosphoinositide 3-kinase), which are important in cardiac conduction; second-generation agents have a substantially lower AF rate. Ibrutinib also inhibits platelet BTK, impairing platelet aggregation and increasing bleeding risk, an effect that requires careful management around surgical procedures.8
Abatacept and belatacept (CTLA-4-Ig fusion proteins) activate the CTLA-4 inhibitory checkpoint to suppress autoimmune T-cell responses. This is the opposite direction from oncology checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab), which block CTLA-4 and PD-1 to release inhibitory constraints on anti-tumor T cells. Consequently, immune-related adverse events (irAEs) from checkpoint inhibitor cancer therapy — including inflammatory arthritis, colitis, thyroiditis, and pneumonitis — are autoimmune in nature and can be treated with corticosteroids; abatacept has shown efficacy in checkpoint inhibitor-induced inflammatory arthritis, illustrating the pharmacological reciprocity between immune activation and suppression at these checkpoints.
A fundamental limitation of B-cell-depleting agents such as rituximab is their inability to eliminate long-lived plasma cells, which lack CD20 (cluster of differentiation 20) expression and are maintained in dedicated bone marrow niches, continuing to secrete pathogenic autoantibodies for months to years after B-cell depletion. This gap has driven the development of plasma cell-directed therapies that target antigens expressed on plasma cells but not on earlier B-cell stages, or that exploit the metabolic vulnerability of secretory cells to proteasome inhibition.
Why Long-Lived Plasma Cells Drive Persistent Autoantibody Production. Plasma cells (PCs) are terminally differentiated antibody-secreting cells that exit the cell cycle and no longer express CD20 or other B-cell surface markers recognized by standard B-cell-depleting therapies. Upon antigenic stimulation, germinal center reactions generate affinity-matured B cells that differentiate into short-lived plasmablasts (circulating, proliferating, lasting days to weeks) and long-lived plasma cells that migrate to survival niches in the bone marrow, where they receive survival signals from stromal cells through APRIL (a proliferation-inducing ligand, also called TNFSF13), BAFF (B-cell activating factor, also called TNFSF13B), interleukin-6 (IL-6), and contact interactions with bone marrow stromal cells via CXCL12/CXCR4 (C-X-C motif chemokine ligand 12/receptor 4) interactions. Long-lived plasma cells can persist in these niches for years to decades and continue producing high levels of antigen-specific antibodies long after the initial B-cell activation event. In diseases such as pemphigus vulgaris, myasthenia gravis, anti-GBM (glomerular basement membrane) nephritis, and systemic lupus erythematosus (SLE) with persistent high anti-dsDNA titers, long-lived plasma cells maintain the pathogenic autoantibody response despite rituximab-mediated B-cell depletion, providing the rationale for plasma cell-directed therapy.10
Daratumumab: Anti-CD38 Plasma Cell Depletion. Daratumumab is a fully human IgG1 monoclonal antibody directed against CD38 (cluster of differentiation 38), a transmembrane glycoprotein highly expressed on plasma cells (including both neoplastic myeloma cells and non-neoplastic long-lived plasma cells), plasmablasts, and a subset of T cells and natural killer (NK) cells; it is expressed at lower levels on B cells, monocytes, and other hematopoietic lineages. Daratumumab depletes CD38-expressing cells through multiple effector mechanisms: antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells and macrophages, complement-dependent cytotoxicity (CDC), ADCP (antibody-dependent cellular phagocytosis), and direct induction of apoptosis. Daratumumab is approved for multiple myeloma (as monotherapy and in combination regimens) and for light chain amyloidosis. In autoimmune disease, daratumumab is under investigation and has shown dramatic responses in case series of patients with refractory antibody-mediated autoimmune conditions including myasthenia gravis, SLE, pemphigus vulgaris, and anti-GBM disease, producing rapid and deep depletion of both short-lived and long-lived plasma cells. An important safety consideration is that CD38 is also expressed on NK cells, whose depletion by daratumumab impairs immune surveillance and increases susceptibility to viral infections, particularly herpesvirus reactivation; antiviral prophylaxis is recommended. CD38 expression on erythrocytes causes a pan-reactive positive direct antiglobulin test (DAT) and can interfere with blood compatibility testing, requiring specialized pre-transfusion testing in patients receiving daratumumab.11
Bortezomib: Proteasome Inhibition and Plasma Cell Vulnerability. Bortezomib is a dipeptide boronic acid proteasome inhibitor that reversibly inhibits the 26S proteasome, specifically the beta5 (chymotrypsin-like) catalytic subunit of the 20S proteasome core particle. Plasma cells are uniquely vulnerable to proteasome inhibition because their extremely high rate of immunoglobulin synthesis generates a massive burden of misfolded or unassembled protein chains that must be degraded by the proteasome through the unfolded protein response (UPR); when proteasome function is blocked, misfolded immunoglobulin accumulates, activating the terminal UPR pathway and triggering apoptosis through IRE1 (inositol-requiring enzyme 1), PERK (protein kinase R-like endoplasmic reticulum kinase), and ATF6 (activating transcription factor 6). Other antibody-secreting cells such as plasmablasts are similarly vulnerable. Bortezomib is approved for multiple myeloma and mantle cell lymphoma; in autoimmune disease, bortezomib has been used off-label for refractory antibody-mediated conditions including antibody-mediated transplant rejection, lupus nephritis, and neuromyelitis optica, with modest but sometimes dramatic clinical responses correlating with reductions in pathogenic autoantibody titers. The major dose-limiting toxicity of bortezomib is peripheral neuropathy (predominantly sensory, occurring in 30 to 40% of patients), which led to the development of carfilzomib (an irreversible proteasome inhibitor with lower neuropathy rates) and ixazomib (an oral proteasome inhibitor).10
The most complete depletion of autoantibody-producing cells would ideally target both the B-cell precursor pool (preventing new autoantibody-producing cell generation) and the long-lived plasma cell reservoir (eliminating existing autoantibody production). Clinical strategies under investigation combine rituximab or obinutuzumab (anti-CD20) with daratumumab (anti-CD38) to sequentially deplete B cells and long-lived plasma cells, an approach showing early promise in refractory SLE and pemphigus. Alternatively, CAR-T (chimeric antigen receptor T-cell) therapy directed against CD19, CD38, or BCMA (B-cell maturation antigen) depletes all stages of B-cell lineage including plasma cells and has demonstrated dramatic responses in small cohorts of patients with refractory autoimmune diseases including SLE, myositis, and systemic sclerosis. These emerging approaches represent the frontier of precision autoimmune therapy, where the depth and durability of immune reset is determined by how completely the pathogenic lymphocyte population is eliminated.
The pharmacological complexity of immunosuppressive therapy is increasingly matched by the availability of biological markers that allow rational, patient-specific drug selection and individualized monitoring. Precision immunopharmacology integrates knowledge of disease immunopathology, drug mechanisms, pharmacokinetics, and biomarker-guided feedback to optimize therapeutic outcomes while minimizing unnecessary immunosuppression.
Therapeutic Drug Monitoring in Biologic Therapy. Therapeutic drug monitoring (TDM) is the measurement of drug trough levels and anti-drug antibodies (ADAs) in serum to guide dosing decisions. TDM has the strongest evidence base in tumor necrosis factor (TNF) inhibitor therapy for inflammatory bowel disease, where trough infliximab levels below 3 to 5 micrograms per milliliter and trough adalimumab levels below 5 to 7 micrograms per milliliter correlate with secondary loss of response due to sub-therapeutic drug exposure, most commonly caused by anti-drug antibody (ADA) formation. Reactive TDM (measuring levels only when secondary loss of response occurs) and proactive TDM (measuring levels at defined intervals to prevent loss of response through dose optimization) have both been shown to improve outcomes in IBD (inflammatory bowel disease). The general principle underlying TDM in biologic therapy is that drug concentrations must exceed the threshold required to neutralize excess soluble target (e.g., TNF) in tissues; when target concentrations increase (due to disease flare or ADA-mediated drug clearance), trough drug levels fall below therapeutic threshold. TDM guides the decision between dose escalation (for sub-therapeutic levels without ADA), switching within class (for sub-therapeutic levels with high ADA), and switching out of class (for primary non-response or immunogenic failure).12
Biomarkers of Disease Activity and Treatment Response. Multiple biomarkers are used to monitor disease activity and treatment response in autoimmune disease. C-reactive protein (CRP) is the most widely used acute-phase reactant for monitoring inflammatory disease activity in rheumatoid arthritis (RA), IBD, and vasculitis; however, CRP is unreliable in patients receiving interleukin-6 (IL-6) receptor inhibitors (IL-6R inhibitors) (tocilizumab, sarilumab), as discussed in Immuno-03, and in systemic lupus erythematosus (SLE), where CRP frequently does not reflect lupus disease activity (though it rises with intercurrent infection). Procalcitonin (PCT) is a superior infection biomarker to CRP in patients on IL-6R inhibitors, and is unaffected by most immunosuppressive agents. The erythrocyte sedimentation rate (ESR) reflects fibrinogen and immunoglobulin levels and is used in monitoring vasculitis (giant cell arteritis, GCA) and some connective tissue diseases, but is less specific than CRP for acute inflammation. Disease-specific autoantibody titers are used for treatment monitoring in antibody-mediated diseases: anti-dsDNA titers in SLE (rising titers correlate with lupus nephritis flare risk), anti-AChR titers in myasthenia gravis, anti-PLA2R (phospholipase A2 receptor) antibodies in membranous nephropathy, and anti-AQP4 titers in neuromyelitis optica spectrum disorder (NMOSD). Complement levels (C3, C4, CH50) are used to assess complement consumption in SLE and complement-mediated diseases.2
Biomarker-Guided Drug Selection: The Precision Medicine Framework. The ideal of precision immunopharmacology is to match the right drug to the right patient based on the specific immunopathological mechanisms driving their disease. Several examples of emerging biomarker-guided drug selection illustrate this principle. The interferon gene signature (ISG score), detected on gene expression profiling of peripheral blood cells, is positive in 60 to 80% of SLE patients and identifies patients more likely to respond to anifrolumab (which blocks the type I interferon receptor); conversely, patients with a low ISG score may be better served by belimumab or conventional immunosuppression. In paroxysmal nocturnal hemoglobinuria (PNH), clone size (the proportion of GPI (glycosylphosphatidylinositol)-deficient blood cells detected by flow cytometry) and the severity of intravascular versus extravascular hemolysis determine whether anti-C5 therapy (eculizumab/ravulizumab), proximal complement inhibition (pegcetacoplan), or alternative pathway inhibition (iptacopan, danicopan add-on) is most appropriate. In ANCA (anti-neutrophil cytoplasmic antibody) vasculitis, the distinction between anti-PR3 (proteinase-3) and anti-MPO (myeloperoxidase) ANCA has practical implications: PR3-ANCA (proteinase-3 ANCA) is more often associated with GPA (granulomatosis with polyangiitis) and higher relapse rates, and rituximab may be preferred over cyclophosphamide for induction in this subgroup. The blood eosinophil count guides anti-IL-5 biologic selection in severe asthma.
Vaccination Strategy and Infection Prophylaxis in Immunosuppressed Patients. A cornerstone of safe immunosuppressive therapy management is the optimization of vaccination before initiation and the application of infection prophylaxis protocols during ongoing therapy. Beyond the agent-specific vaccines already covered in earlier modules (tuberculosis (TB) screening, hepatitis B virus (HBV) prophylaxis, meningococcal vaccination for complement inhibitors, Shingrix for Janus kinase (JAK) inhibitors), general principles apply across all immunosuppressive agents. Live attenuated vaccines (MMR (measles-mumps-rubella), varicella-zoster live vaccine, yellow fever, oral typhoid, live-attenuated influenza vaccine (LAIV)) are contraindicated once any significant immunosuppressive therapy is started, because vaccine-strain organisms may cause disseminated infection in the absence of normal immune surveillance. All inactivated and subunit vaccines can be administered during immunosuppressive therapy, though immunogenicity may be reduced (the degree of attenuation depends on the specific agent and degree of immunosuppression). Annual inactivated influenza vaccination, pneumococcal vaccination using a 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent vaccine (PCV20), followed by the 23-valent polysaccharide vaccine (PPSV23) at appropriate intervals, and coronavirus disease 2019 (COVID-19) vaccination are recommended in all immunosuppressed patients. Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) is indicated in patients receiving high-dose corticosteroids (prednisolone greater than 20 mg/day for more than 4 weeks) combined with additional immunosuppressants, in patients receiving certain biologic agents (rituximab, daratumumab), and in solid organ transplant recipients.
Target specificity determines the safety profile: The more upstream and broadly a drug acts (corticosteroids, calcineurin inhibitors, mycophenolate), the broader the immunosuppression and the more diverse the adverse effects. The more specific the target (anti-C5 in PNH, anti-IL-17A in psoriasis, anti-IFNAR1 in SLE), the more targeted the effects but the more risk of losing a specific immune defense. Mechanism determines which infections to screen for and monitor: TB for anti-TNF; HBV for all biologics; meningococcal for complement inhibitors; herpes zoster for JAK inhibitors; JC virus for rituximab. Biomarkers guide selection and monitoring: ISG score for anifrolumab; interferon-alpha for type I IFN diseases; PNH clone size for complement inhibitor choice; anti-drug antibodies for biologic TDM; ADA and drug levels for IBD biologic optimization. No single agent suppresses all pathogenic pathways — the art of immunopharmacology lies in matching the predominant pathological mechanism to the most precisely targeted pharmacological intervention.
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797.
doi:10.1038/ni.1923Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479-492.
doi:10.1016/j.semnephrol.2013.08.001Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552-559.
doi:10.1056/NEJMoa031688Peffault de Latour R, Brodsky RA, Ortiz S, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2020;105(8):2039-2046.
doi:10.3324/haematol.2019.226108Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599-609.
doi:10.1056/NEJMoa2023386Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176-189.
doi:10.1038/nri3401Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770-781.
doi:10.1056/NEJMoa050085Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32(17):1830-1839.
doi:10.1200/JCO.2013.53.1046Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
doi:10.1182/blood-2010-02-271171Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160-171.
doi:10.1038/nri3795Chung A, Tumlin J, Kooienga L, et al. Daratumumab in autoimmune diseases: a mechanism-based review. Am J Hematol. 2023;98(6):998-1010.
doi:10.1002/ajh.26887Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835-857.e6.
doi:10.1053/j.gastro.2017.07.031